

4.0.03 DOC Cmte minutes

RRT Committee meeting

Date: 17/05/2017

Location: Boardroom, National Guideline Centre (NGC)

Minutes: Confirmed

Committee members present:		
Jan Dudley (Chair) (JD)		(Present for notes 1 – 8)
Andrew Mooney (AM)		(Present for notes 1 – 8)
Virginia Aylett (VA)		(Present for notes 1 – 8)
Caryl Bryant (CB)		(Present for notes 1 – 8)
Ruth Crowther-Wood (RCW)		(Present for notes 1 – 8)
Martin Drage (MD)		(Present for notes 1 – 8)
Bimbi Fernando (BF)		(Present for notes 1 – 6)
Hugh Gallagher (HG)		(Present for notes 1 – 8)
Fiona Loud (FL)		(Present for notes 1 – 8)
Rajib Pal (RP)		(Present for notes 1 – 8)
Catherine O’Leary (COL)		(Present for notes 1 – 8)
Nii Plange (NP)		(Present for notes 1 – 8)
Lynne Russon (LR)		(Present for notes 1 – 8)
Rukshana Shroff (RS)		(Present for notes 1 – 8)
Nicola Thomas (NT)		(Present for notes 1 – 8)
Raj Thuraisingham (RT)		(Present for notes 1 – 8)

In attendance:		
Sharon Swain (SS)	Associate Director/Guideline Lead	(Present for notes 1 – 8)
James Gilbert (JG)	Senior Research Fellow	(Present for notes 1 – 8)
Katrina Davis (KD)	Research Fellow	(Present for notes 1 – 4)
Kate Lovibond (KL)	Health Economics Lead	(Present for notes 1 – 8)
Nick Staples (NS)	Guideline Commissioning Manager, NICE	(Present for notes 5 – 8)
Giulia Zuodar (GZ)	Project Manager	(Present for notes 1 – 8)

4.0.03 DOC Cmte minutes

Apologies:

Katie Broomfield, Document Editor, NGC

Mark Prentice (MP), Committee Member, NGC

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the fifth meeting of this committee.

No members of the public asked to observe the meeting.

Apologies were received from KB and MP.

2. Confirmation of matter under discussion, and declarations of interest

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting. New interests declared:

GC Declarations of Interest

N.B. The Chair and GC members were recruited to this guideline using NICE DOI policy published September 2014.

Insert initials	Declaration	Classification (as per the NICE DOI policy wording*)	Chair's action
NT	Guest speaker at British Renal Society conference, Nottingham 26-28 April 2017. Reimbursed travel expenses and no charge for accommodation. No payment.	<ul style="list-style-type: none"> Personal non-financial specific 	Declare and participate
RP	Participated in the development of the Renal Association AKI guidelines Took part in MIMS Learning GP update	<ul style="list-style-type: none"> Personal non-financial specific Personal non-financial non-specific 	<ul style="list-style-type: none"> Declare and participate Declare and participate
RS	1. On advisory committee for Astra-Zeneca for developing a	<ul style="list-style-type: none"> Personal financial non-specific 	<ul style="list-style-type: none"> Declare and participate

4.0.03 DOC Cmte minutes

	<p>clinical trial of an SGLT-2i agent called dapagliflozin (drug to reduce proteinuria)</p> <p>2. Leading on a guideline on Vascular access in children requiring dialysis – ESPN initiative</p> <p>3. Participation in a guideline on Growth Hormone therapy in children with CKD, on dialysis and after transplantation_ESPN initiative</p> <p>4. Attendance at a meeting sponsored by Nestle</p>	<ul style="list-style-type: none"> • Personal non-financial specific • Personal non-financial non-specific • Personal financial non-specific 	<ul style="list-style-type: none"> • Declare and withdraw from recommendations on Vascular access • Declare and participate • Declare and participate
AM	Attended British Renal Society Conference	<ul style="list-style-type: none"> • Personal non-financial specific 	<ul style="list-style-type: none"> • Declare and participate
VA	Attended Royal College of Physicians Conference in Manchester on 17/03/17, which received drug company sponsorship. I did not receive any sponsorship to attend.	<ul style="list-style-type: none"> • Personal non-financial specific 	Declare and participate

4.0.03 DOC Cmte minutes

LR	Presented at British Renal Society meeting – 17 April, no sponsorship, only received travel expenses	<ul style="list-style-type: none"> • Personal non-financial specific 	Declare and participate
RT	<ul style="list-style-type: none"> • Attended Renal Association Clinical Director Forum, lunch sponsored by Angen 	<ul style="list-style-type: none"> • Personal non-financial specific 	Declare and participate
FL	<ul style="list-style-type: none"> • Attended British Renal Society Conference in April 2017 as a speaker, expenses paid. • Attended Clinical Director Forum May 2017, lunch paid by Angen • Spoke at NXstage clinical staff meeting re working the BKPA. No funding or expenses. • Attended one day at a further home therapies roadshow at King's Hospital, May 2017. Funding as per previous declaration – none direct, to BKPA 	<ul style="list-style-type: none"> • Personal non-financial specific • Personal non-financial specific • Personal non-financial specific • Personal non-financial specific 	<ul style="list-style-type: none"> • Declare and participate • Declare and participate • Declare and participate • Declare and participate

4.0.03 DOC Cmte minutes

<p>NICE DOI policy classifications are:</p> <ul style="list-style-type: none">• Personal financial specific• Personal financial non-specific• Personal non-financial specific• Personal non-financial non-specific• Non-personal financial specific• Non-personal financial non-specific			
<p>The Chair and a senior member of the Developer's team noted that in relation to the previous declarations recorded in the DOI register, for this meeting, the following actions should apply:</p> <p>RS is involved in research funded by Kidney Research UK into the effects of haemodiafiltration vs conventional haemodialysis on growth and cardiovascular markers in children. The Chair agreed that she should declare and participate to the discussion, but not to recommendations for this specific topic within the Modalities evidence review.</p>			
3. Minutes and notes from GC4			
The minutes and notes were then accepted as an accurate record of the meeting.			
4. Evidence review: RRT modalities			
<p>4.1 The GC was given a presentation on the clinical and economic evidence for RRT modalities:</p> <ul style="list-style-type: none">• New evidence on conservative management and subgroups; update on transplant; HDF and frequency• Factors suggesting that certain forms of renal replacement therapy may be more appropriate for certain groups of people• Conservative management vs RRT• HE model update <p><u>For the discussion of the recommendations on the comparison HDF vs HD RS stepped out of the room as agreed with the Chair.</u></p>			
5. Evidence review: What assessment is needed			

4.0.03 DOC Cmte minutes

5.1 The GC was given a presentation on the clinical and economic evidence for the question on the assessment needed for people for whom RRT or conservative management may be appropriate.

6. Evidence review: When to assess

6.1 The GC was given a presentation on the clinical and economic evidence for the question on when should people be assessed RRT or conservative management.

7. Protocols

6.1 The GC signed off the protocols for the diet and fluid management question and for the question on planning dialysis access formation.

8. Any other business

None

Date of next meeting: 22/06/2017 and 23/06/2017

Location of next meeting: Boardroom, NGC, and Wolfson Conference and Exhibition Space, 41 Portland Place